Q4 Earnings Forecast for Natera Issued By Leerink Partnrs

Natera, Inc. (NASDAQ:NTRA - Free Report) - Equities research analysts at Leerink Partnrs raised their Q4 2026 earnings estimates for shares of Natera in a note issued to investors on Monday, July 21st. Leerink Partnrs analyst P. Souda now expects that the medical research company will post earnings of ($0.37) per share for the quarter, up from their previous forecast of ($0.38). The consensus estimate for Natera's current full-year earnings is ($1.49) per share.

A number of other equities research analysts also recently weighed in on the stock. Wall Street Zen downgraded shares of Natera from a "hold" rating to a "sell" rating in a research note on Saturday, May 17th. Barclays lifted their price objective on shares of Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a research note on Friday, May 9th. UBS Group lifted their price objective on shares of Natera from $211.00 to $218.00 and gave the stock a "buy" rating in a report on Friday, May 9th. Finally, Piper Sandler boosted their price target on shares of Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. One investment analyst has rated the stock with a sell rating and fifteen have issued a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and an average target price of $184.63.

Natera Stock Performance

Shares of NTRA stock traded down $2.17 on Wednesday, hitting $138.90. The company's stock had a trading volume of 1,202,980 shares, compared to its average volume of 1,211,392. The stock's 50 day moving average is $158.80 and its 200-day moving average is $157.12. Natera has a fifty-two week low of $92.14 and a fifty-two week high of $183.00. The company has a market capitalization of $18.97 billion, a PE ratio of -94.49 and a beta of 1.73.

Natera (NASDAQ:NTRA - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The medical research company reported ($0.50) earnings per share for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. The firm had revenue of $501.83 million for the quarter, compared to analyst estimates of $446.68 million. Natera had a negative net margin of 10.36% and a negative return on equity of 18.29%. The business's revenue was up 36.5% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.56) earnings per share.

Insider Transactions at Natera

In other news, Director Gail Boxer Marcus sold 4,299 shares of the company's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total value of $719,480.64. Following the sale, the director directly owned 8,118 shares of the company's stock, valued at $1,358,628.48. This represents a 34.62% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Steven Leonard Chapman sold 6,980 shares of Natera stock in a transaction dated Thursday, May 1st. The stock was sold at an average price of $150.10, for a total value of $1,047,698.00. Following the completion of the transaction, the chief executive officer directly owned 185,182 shares of the company's stock, valued at approximately $27,795,818.20. This represents a 3.63% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 58,271 shares of company stock valued at $9,075,247. 7.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Guided Capital Wealth Management LLC raised its holdings in Natera by 0.5% during the 2nd quarter. Guided Capital Wealth Management LLC now owns 13,135 shares of the medical research company's stock valued at $2,219,000 after buying an additional 66 shares during the period. Fulton Bank N.A. increased its stake in shares of Natera by 2.0% during the first quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company's stock valued at $516,000 after buying an additional 71 shares during the period. Wedmont Private Capital boosted its position in Natera by 4.9% during the second quarter. Wedmont Private Capital now owns 1,580 shares of the medical research company's stock valued at $256,000 after purchasing an additional 74 shares in the last quarter. Compound Planning Inc. boosted its position in Natera by 4.2% during the first quarter. Compound Planning Inc. now owns 1,914 shares of the medical research company's stock valued at $271,000 after purchasing an additional 78 shares in the last quarter. Finally, QRG Capital Management Inc. boosted its holdings in Natera by 1.5% in the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock worth $766,000 after acquiring an additional 81 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.